Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis
JAMA 32:165-174,153, Burt, R.K.,et al, 2019
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
NEJM 365:1293-1303, OConnor, P.,et al, 2011
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010
Acute Limbic Encephalitis and Glutamic Acid Decarboxylase Antibodies:A Reality?
J Neurosci 287:69-71, Blanc,F.,et al, 2009
Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis
Arch Neurol 65:1044-1051, Krishnan,C.,et al., 2008
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
NEJM 355:1124-1140, Kappos,L.,et al, 2006
Effect of Mitoxantrone on MRI in Progressive MS, Results of the MIMS Trial
Neurol 65:690-695, Krapf,H.,et al, 2005
Mitoxantrone for Multiple Sclerosis in Clinical Practice
Neurol 63(Suppl 6):S25-S27, Rizvi,S.A.,et al, 2004
Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997
Low-Dose Oral Methotrexate in Chronic Progressive Multiple Sclerosis:Analyses of Serial MRIs
Neurol 47:1153-1157, Goodkin,D.E.,et al, 1996
Linomide Reduces the Rate of Active Lesions in Relapsing-Remitting Multiple Sclerosis
Neurol 47:895-900, Anderson,O.,et al, 1996
Low-Dose (7. 5mg) Oral Methotrexate Reduces the Rate of Progression in Chronic Progressive Multiple Sclerosis
Ann Nuerol 37:30-40, 51995., Goodkin,D.E.,et al, 1995
Cladribine in Treatment of Chronic Progressive Multiple Sclerosis
Lancet 344:3-13, Sipe,J.C.,et al, 1994
Intermittent Cyclophosphamide Pulse Therapy in Progressive MS:NE Coop MS Trtm Grp
Neurol 43:910-918, Weiner,H.L.,et al, 1993
"Chronic Sensory Demyelinating Neuropathy":CIDP Presenting as a Pure Sensory Neuropathy
JNNP 55:677-680, Oh,S.J.,et al, 1992
The Efficacy of Azathiorpine in Relapsing-Remitting Multiple Sclerosis
Neurol 41:20-25, Goodkin,D.E.,et al, 1991
The Canadian Coop Trial of Cyclophosphamide and Plasma Exchange in Progr MS
The Canadian Coop MS Study Group, Lancet 337:441-4461991., , 1991
Plasma Exchange in Chronic Progressive Multiple Sclerosis:A Long-Term Study
Neurol 41:409-414, Khatri,B.O.,et al, 1991
Overview of Azathioprine Treatment in Multiple Sclerosis
Lancet 338:1051-1055, Yudkin,P.L.,et al, 1991
Intense Immunosuppression in Chronic Progressive Multiple Sclerosis:The Kaiser Study
JNNP 54:1055-1060, Likosky,W.H.,et al, 1991
Efficacy & Toxicity of Cyclosporine in Chronic Progressive Multiple Sclerosis:A Randomized Clinical Trial
M. S. Study Group, Ann Neurol 27:591-605, 5890., , 1990
Double-Blind Study of True vs. Sham Plasma Exchange in Patients Treated with Immunosuppression for Acute Attacks of MS
Neurol 39:1143-1149, Weiner,H.L.,et al, 1989
A Placebo-Controlled, Randomized, Clinical Trial of Azathioprine with & without Methylpred in MS
Neurol 39:1018-1026, Ellison,G.W.,et al, 1989
Cyclophosphamide"Pulses"in Chronic Progressive Multiple Sclerosis, A Preliminary Clinical Trial
Arch Neurol 44:828-832, Myers,L.W.,et al, 1987
Cyclophosphamide in Chronic Progressive Multiple Sclerosis, Maintenance vs Nonmaintenance Therapy
Arch Neurol 44:823-827, Goodkin,D.E.,et al, 1987
Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022
Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Diagnosis and Treatment of Neuromyelitis Optica
The Neurologist 13:2-11, Wingerchuk,D.M., 2007
Primary Central Nervous System Vasculitis: Analysis of 101 Patients
Ann Neurol 62:442-451,430, Salvarani,C.,et al, 2007
Clinicopath Conf., Multifocal Motor Neuropathy With Conduction Block
NEJM 357: 2707-2715, Case 40-2007, 2007
Update on Susacs Syndrome
Curr Opin Neurol 18:311-314, Gross,M. &Eliashar,R., 2005
Retinocochleocerebral Vasculopathy
Medicine 77:12-40, Petty,G.W.,et al, 1998
Clinicopath Conf
Primary (Granulomatous) Angiitis of Central Nervous System, Case Record 8-1989, NEJM 320:514-5249., , 1989
Clinicopathologic Features, Pathogenesis, and Treatment of Monoclonal Gammopathy-Associated Myopathies
Neurol 105:213101, Soontrapa,P.,et al, 2025
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Pregnancy in Patients with AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder
Neurol 96:e2006-e2015, Collongues, N.,et al, 2021
A 47-Year-Old With Headache, Vertigo, and Double Vision
Neurol 97:e535-e539, Frey, J.,et al, 2021
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Clinicopathologic Conference, Neurosarcoidosis
NEJM 374:1966-1975, Case 15-2016, 2016
Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 73:757-759, Penkert, H.,et al, 2016
Reactivation of Herpesvirus under Fingolimod: A Case of Severe Herpes Simplex Encephalitis
Neurol 84:2377-2378, Pfender, N.,et al, 2015
Very Late-Onset Neuromyelitis Optica Spectrum Disorder Beyond the Age of 75
J Neurol 262:1379-1384, Krumbholz, M.,et al, 2015
Mycophenolate Mofetil in Multiple Sclerosis: A Multicentre Retrospective Study on 344 Patients
JNNP 85:279-283,246, Michel, L.,et al, 2014